度洛西汀联合喹硫平治疗更年期首发抑郁症的临床研究  

Comparative study of duloxetine with quetiapine in the treatment of menopausal women with first-episode depression

作　　者：马元业 王华永[1] 张保健[1] 周文娟[1] 董志强[1] 

机构地区：[1]甘肃省天水市第三人民医院,741000

出　　处：《四川精神卫生》2012年第4期216-218,共3页Sichuan Mental Health

摘　　要：目的探讨度洛西汀联合喹硫平治疗更年期女性首发抑郁症患者的疗效及安全性。方法将70例更年期女性首发抑郁症患者随机分为度洛西汀联合喹硫平组(研究组)和度洛西汀组(对照组),两组各35例,疗程8周。采用汉密尔顿抑郁量表(HAMD17)和汉密尔顿焦虑量表(HAMA)评定疗效,用治疗时出现的症状量表(TESS)评定安全性。结果研究组有效率为80.0%,对照组有效率为77.1%,提示两组疗效相当(P>0.05);治疗8周后,两组HAMD17和HAMA评分较治疗前均有显著下降(P均<0.05),两组间比较其差异无统计学意义(P均>0.05),但在第2、4周末研究组HAMD17和HAMA评分下降较对照组显著,两组间比较其差异则有统计学意义(P均<0.05)。安全性方面,两组间比较其差异无统计学意义(P>0.05)。结论度洛西汀联合喹硫平治疗更年期女性首发抑郁症起效快、疗效好、安全性高。Objective To study the efficacy and safety of duloxetine with quetiapine in the treatment of menopausal women with first-episode depression.Methods 70 menopausal women with first-episode depression were randomly assigned to duloxetine with quetiapine group and duloxetine group.35 patients received duloxetine with quetiapine while 35 patients were treated with duloxetine for 8 weeks.The efficacy was assessed with HAMD17 and HAMA and adverse reactions with TESS.Results There are not difference between the two groups in efficacy.While the scores of the HAMD17 and HAMA of duloxetine with quetiapine group significantly decreased than duloxetine group at the second and fourth weekend.There were not difference between the two groups on adverse reactions.Conclusion Duloxetine with quetiapine takes effect faster,and has better effect and higher safety in the treatment of menopausal women with first-episode depression.

关 键 词：度洛西汀 喹硫平 首发抑郁症 

分 类 号：R749.4[医药卫生—神经病学与精神病学]